Business Wire

25 Years of Trust, Quality, and Health: SFI Health™ celebrates Equazen® milestone, the brand of food supplements developed to support cognitive needs

26.3.2025 08:00:00 CET | Business Wire | Press release

Share

- From a pioneering intuition on the benefits of essential fatty acids for the human brain to becoming a global brand trusted by families and healthcare professionals

SFI Health is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326323152/en/

Discover Equazen® comprehensive range: multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. For more info visit www.equazen.com

The story of Equazen® began in 1999 in the UK with Prof. Horrobin’s groundbreaking research. Guided by his intuition, he researched certain pediatric cognitive function disorders stemming from a lack of essential fatty acids and their precursors. This insight led to the development of the first Equazen® product, originally known as Eye Q.

The product featured a unique combination of essential fatty acids, setting the foundation for Equazen®’s evolution while aligning with the company’s core philosophy: to harness the power of naturally sourced ingredients and adopt a pharma-quality approach to food supplements.

Since the publication of its first clinical evidence in 2005, Equazen® has been supported by over two decades of clinical trials. As a result, the brand is trusted globally by business partners, families and healthcare professionals to enhance learning capabilities, concentration, and overall cognitive well-being.

At the same time, Equazen® has evolved into multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers.

One of the latest innovations is Equazen® Jelly, which combines the unique blend of essential fatty acids with a fruity flavor designed to appeal to picky eaters. Additionally, its patent-protected technology ensures the jelly is easy to swallow and promotes better natural absorption.

Matthew Brabazon, GM of SFI Heath EMEA, the regional entity of SFI Health, commented: It’s been an incredible journey watching Equazen® grow over the past 25 years to become a trusted brand globally. Looking ahead, we remain focused on the future and have exciting plans to continue bringing innovation to the market.”

Zbyszek Czop, Managing Director of Qpharma Sp. z o.o., distributor of Equazen® in Poland said: Earning the trust of doctors through the positive results of clinical studies on Equazen® is incredibly gratifying. Healthcare professionals now believe that Equazen® can make a meaningful difference for children, particularly those with behavioral disorders.”

Kirsten Jorsal, Founder of Novasel EU,distributor of Equazen® in Denmark added: Equazen® is a unique fatty acid supplement, distinguished by its balanced blend of polyunsaturated fatty acids, with a notably higher EPA content compared to DHA. Along with its strong clinical documentation, it stands apart from other fish oil supplements. Working with this product for so many years has been both rewarding, and receiving feedback from satisfied families has been truly fulfilling.”

A deep knowledge of consumers’ needs continues to guide the brand and inspires future innovations. The Equazen® range is proudly available in 30 countries across all continents, and the company is dedicated to expanding its reach, ensuring more consumers worldwide can benefit from its offerings.

About SFI Health

SFI Health is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.

Guided by the belief in the healing potential of natural products, SFI Health combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.

An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.

SFI Health is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.

For more information go to sfihealth.com or follow us SFI Health on LinkedIn.

About Equazen®

Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.

Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.

Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.

Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.

Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.

For more info visit www.equazen.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326323152/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wolters Kluwer advances Libra legal AI workspace with enhanced contract review and integrated workflows5.5.2026 09:00:00 CEST | Press release

New release introduces more seamless experience for end-to-end legal work Wolters Kluwer Legal & Regulatory today announced a new release of Libra by Wolters Kluwer, its legal AI workspace integrating major workflow capabilities with trusted, expert-generated content. The update introduces significant advancements in contract review, workflow integration and usability, and strengthens Libra’s role as an all-in-one platform where legal professionals can research, draft, review and analyze in a connected and integrated environment. Based on customer feedback, the new release focuses on four key areas: stronger organization across projects, a more powerful and flexible review experience, deeper integration between chat and structured workflows, and a refreshed visual and interaction design. Together, these enhancements respond directly to user feedback and reflect Wolters Kluwer’s focus on user-centric, trusted AI. “With this release, we are making a clear step forward in how legal profes

euroAtlantic Airways Appoints Pauls Calitis as CEO to Lead Next Phase of Growth5.5.2026 09:00:00 CEST | Press release

euroAtlantic Airways (“EAA”), a leading global provider of passenger widebody aircraft wet-leasing and charter services, and Njord Partners portfolio company, is pleased to announce the appointment of Pauls Calitis as Chief Executive Officer, effective 18 May 2026. Pauls will succeed Stewart Higginson, who has served as CEO since early 2024 and who will assume the role of Non-Executive Chairman of the Board. The appointment marks the next phase of the company’s development under Njord Partners. Pauls brings more than three decades of expertise in the aviation industry, most recently serving as Chief Operating Officer and Executive Board Member at airBaltic, having also held the role of Interim Chief Executive Officer in 2025. Over his career progressing from pilot to senior executive leadership, he played a central role in the airline’s development and transformation into one of Europe’s most efficient and respected carriers. His leadership helped establish the airline as a benchmark f

SES’s O3b mPOWER Satellite Network to Connect Seven New Petrobras FPSOs5.5.2026 08:50:00 CEST | Press release

New FPSOs will enter into operation in Brazil between 2026 and 2030 to meet the energy sector’s growing demand SES, a leading space solutions company, will provide service on its high-capacity medium-Earth orbit (MEO) satellite network, O3b mPOWER, to Petrobras, the Brazilian state-owned oil company, to connect multiple new Floating Production, Storage and Offloading systems (FPSOs). The projects will go into operation in the coming years, expanding Petrobras’ oil and gas production capacity to meet national energy needs and contribute to global oil markets. FPSOs are modern and efficient oil production platforms, responsible for processing, collecting, storing, and transferring oil to shuttle tankers, directly from subsea wells in deepwater fields. FPSOs offer the flexibility, capacity, and operational resilience needed to sustain large-scale offshore production in remote and challenging environments. Brazil is home to the majority of the offshore projects under development worldwide,

Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 08:00:00 CEST | Press release

Transaction strengthens Regnology’s global position as the go‑to partner for AI‑powered regulatory reporting, risk, and ALM Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Thro

AB InBev Reports First Quarter 2026 Results5.5.2026 07:02:00 CEST | Press release

Solid top- and bottom-line performance: Revenue up by 5.8%, Beer volume growth of 1.2% and a 20.8% Underlying EPS increase Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye